Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Whitehawk Therapeutics, Inc. is an oncology-focused biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that target validated tumor antigens in solid and difficult-to-treat cancers. Leveraging advanced linker-payload technology and proprietary antibodies, Whitehawk aims to improve efficacy and safety by delivering potent Topoisomerase I inhibitor payloads directly to cancer cells. The company operates a virtual model, outsourcing clinical development and manufacturing, targeting global markets with high unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.